Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceuticals since 2005. With a solid background in biotechnology, he previously led Genencor and SangStat Medical Corporation, building his expertise in business development and product commercialization. His career began at Genentech, where...

Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceuticals since 2005. With a solid background in biotechnology, he previously led Genencor and SangStat Medical Corporation, building his expertise in business development and product commercialization. His career began at Genentech, where he played a part in launching groundbreaking treatments for heart attacks. Under his leadership, BioMarin has focused on creating unique therapies for rare diseases, significantly impacting patient lives. Interestingly, his total compensation reached over $21 million in 2023, largely from stock vesting based on past performance. His insider trading activity revealed significant fluctuations in his wealth, reaching up to an impressive $69 million during a peak period in 2020 before stabilizing around $64 million recently. A member of several biotechnology boards, he is committed to advancing the industry, blending a wealth of knowledge with hands-on leadership to drive innovation in healthcare.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other BioMarin Pharmaceuticals CEOs

B

Jean-Jacques Bienaimé

Ex-CEO of BioMarin Pharmaceuticals

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1954 - 71 years ago

CEO of BioMarin Pharmaceuticals for

18 years 6 months (May 2005 - Nov 2023)

Previous Experience

Chairman, President and Chief Executive Officer of Genencor International, Inc.; Chairman, President and Chief Executive Officer of Sangstat Medical Corporation; Senior Vice President of Worldwide Marketing and Business Development at Rhône-Poulenc Rorer Pharmaceuticals; various roles at Genentech, Inc.

Rivals

Competitors/colleagues of Jean-Jacques Bienaimé

Holdings

See how much did Jean-Jacques Bienaimé make over time.

Jean-Jacques Bienaimé's wealth has seen significant shifts over the years, peaking at around $69 million in mid-2020 during a strong year for BioMarin. As of late 2023, his holdings now stabilize around $64 million. These fluctuations reflect his insider trades...

Jean-Jacques Bienaimé's wealth has seen significant shifts over the years, peaking at around $69 million in mid-2020 during a strong year for BioMarin. As of late 2023, his holdings now stabilize around $64 million. These fluctuations reflect his insider trades in BioMarin stock, with notable values reported monthly, showcasing his close connection to the company's market performance. His financial journey shows he had most of his wealth tied up in BioMarin stock during 2020, indicating a strong belief in the company's future, which he has led for nearly two decades.

Mar 18, 2025

B

shares

BMRN @ $71.52

I

shares

INCY @ $60.00

Total Stock Sold

$234.95M

BMRN

$234.95M

2,853,657 BMRN shares

What if they kept their stock?

If Jean-Jacques Bienaimé didn't sell their stock, today they would have:
Extra BMRN2,853,657 shares worth $324.83M.
This is 38.26% and $89.88M more than what they got when they sold the stock.

Charitable Transactions

BMRN

329,607 shares

BMRN

Recent Charitable Transactions

BMRN

5,600 shares

BMRN

Dec 31, 2023

Charity

BMRN

200 shares

BMRN

Feb 7, 2023

Charity

BMRN

100 shares

BMRN

Dec 31, 2022

Charity

BMRN

700 shares

BMRN

Dec 10, 2021

Charity

BMRN

425 shares

BMRN

Jul 9, 2020

Charity

BMRN

630 shares

BMRN

Dec 3, 2019

Charity

Insider Trading

See recent insider trades of Jean-Jacques Bienaimé.

BMRN

$3.26M

BMRN at $81.38/share

May 9, 2024

Sale

BMRN

$3.65M

BMRN at $91.13/share

Apr 11, 2024

Sale

BMRN

$172.22K

BMRN at $86.11/share

Mar 5, 2024

Sale

BMRN

$90.35K

BMRN at $90.35/share

Feb 27, 2024

Sale

BMRN

143,601 shares

BMRN

Feb 27, 2024

Received

BMRN

$2.67M

BMRN at $89.03/share

Jan 18, 2024

Sale

BMRN

$3.70K

BMRN at $92.60/share

Jan 18, 2024

Small Acquisition

BMRN

$1.95M

BMRN at $97.29/share

Jan 8, 2024

Sale

BMRN

$4.95K

BMRN at $99.05/share

Jan 8, 2024

Small Acquisition

Compensation History

See how much did Jean-Jacques Bienaimé make over time.

Jean-Jacques Bienaimé’s 2023 compensation package totaled about $21.9 million, which included a base salary of $1.39 million and a bonus of $1.67 million for his contributions during the year. He benefited significantly from $19.53 million of vested stock, which comprises performance and service-based shares earned from previous years. Notably, while no new stock grants were given as he transitions from the CEO role, his compensation reflects the company’s ongoing strategy to reward top management based on corporate performance in a competitive sector focused on developing new drugs. This pay structure underlines the importance of aligning executive interests with shareholder value.

Year

2023

Total Compensation

$23.10M

Salary

$1.39M

Board Justification

The compensation philosophy is designed to attract and retain executive talent while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$1.67M

Board Justification

Mr. Bienaimé’s annual cash incentive for 2023 as if he had remained employed as CEO in recognition of Mr. Bienaimé’s 2023 contribution and in light of the fact that he served as CEO for most of the year.

Other

$508.00K

Board Justification

This includes various forms of compensation such as health benefits, security measures, and consulting fees following his retirement.

Restricted Stock

$19.53M(211.07K RSU)

Board Justification

The stock that vested in 2023 includes service-based RSUs and performance-based RSUs granted in prior years that were earned based on performance metrics over the applicable periods.

Performance Metrics

The performance metrics for the annual cash incentive included Managed Sales Revenue and Non-GAAP Income targets.

Other BioMarin Pharmaceuticals CEOs

Here are other CEOs of BioMarin Pharmaceuticals

Alexander Hardy

CEO of BioMarin Pharmaceuticals

December 2023 - Present